Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNV2197944 versus placebo crossover study in post-herpetic neuralgia
2012-002903-16Phase 2Completed
- Sponsor
- Convergence Pharmaceuticals
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CNV-2197944 in postherpetic neuralgia (PHN) (2 arms), sponsored by Convergence Pharmaceuticals. Primary endpoint: Change in average daily neuropathic pain score. Started Feb 2013; status: completed.
02
Drugs
CNV-2197944
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on 2012-002903-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002903-16.